Your session will expire automatically in 0 seconds.
LEADER 00000cam a2200253 a 4500
001 u45697
003 SIRSI
008 080621s2018 xxua b 001 0 eng d
020 9783030092214
050 00 RE661.D3 |bR48 2018
245 10 Retinal degenerative diseases :|bmechanisms and
experimental therapy /|cedited by John D. Ash, Robert E.
Anderson, Matthew M. LaVail, Catherine Bowes Rickman, Joe
G. Hollyfield, Christian Grimm.
250 1st ed. 2018.
260 Cham : |b Springer International Publishing : |b Imprint:
Springer, |c 2018.
300 XLII, 669 p :|b142 illustrations, 93 illustrations in
color ;|c24 cm.
490 Advances in Experimental Medicine and Biology, |x 0065-
2598 ; |v 1074
500 "The XVI International Symposium on Retinal Degeneration
(also known as RD2014) was held from July 13-18, 2014 at
the Asilomar Conference Center, Pacific Grove, California,
USA"--Page vii.
504 Includes bibliographical references and index.
520 The blinding diseases of inherited retinal degenerations
have no treatments, and age-related macular degeneration
has no cures, despite the fact that it is an epidemic
among the elderly, with 1 in 3-4 affected by the age of
70. The RD Symposium will focus on the exciting new
developments aimed at understanding these diseases and
providing therapies for them. Since most major scientists
in the field of retinal degenerations attend the biennial
RD Symposia, they are known by most as the "best" and
"most important" meetings in the field. The volume will
present representative state-of-the-art research in almost
all areas of retinal degenerations, ranging from
cytopathologic, physiologic, diagnostic and clinical
aspects; animal models; mechanisms of cell death;
candidate genes, cloning, mapping and other aspects of
molecular genetics; and developing potential therapeutic
measures such as gene therapy and neuroprotective agents
for potential pharmaceutical therapy. While advances in
these areas of retinal degenerations will be described,
there will be many new topics that either were in their
infancy or did not exist at the time of the last RD
Symposium, RD2014. These include the role of inflammation
and immunity, as well as other basic mechanisms, in age-
related macular degeneration, several new aspects of gene
therapy, and revolutionary new imaging and functional
testing that will have a huge impact on the diagnosis and
following the course of retinal degenerations, as well as
to provide new quantitative endpoints for clinical trials.
The retina is an approachable part of the central nervous
system (CNS), and there is a major interest in
neuroprotective and gene therapy for CNS diseases and
neurodegenerations, in general. It should be noted that
with successful and exciting initial clinical trials in
neuroprotective and gene therapy, including the
restoration of sight in blind children, the retinal
degeneration therapies are leading the way towards new
therapeutic measures for neurodegenerations of the CNS.
Many of the successes recently reported in these areas of
retinal degeneration sprang from collaborations
established at previous RD Symposia, and many of those
will be reported at the RD2018 meeting and included in the
proposed volume. We anticipate the excitement of those
working in the field and those afflicted with retinal
degenerations will be reflected in the volume.
650 0 Neurosciences.
650 0 Ophthalmology.
650 0 Neurosciences. |0 https://scigraph.springernature.com/
ontologies/product-market-codes/B18006
650 0 Ophthalmology. |0 https://scigraph.springernature.com/
ontologies/product-market-codes/H44004
700 1 Anderson, Robert E. |e editor.
700 1 Ash, John D. |e editor.
700 1 Bowes Rickman, Catherine. |e editor.
700 1 Grimm, Christian. |e editor.
700 1 Hollyfield, Joe G. |e editor.
700 1 LaVail, Matthew M. |e editor.
830 0 Advances in experimental medicine and biology ;|vv. 854